INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 72 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2013. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,226,000 | -6.6% | 53,100 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $1,312,000 | -46.4% | 53,100 | -10.1% | 0.00% | -50.0% |
Q3 2020 | $2,450,000 | -10.9% | 59,093 | +3.0% | 0.00% | -33.3% |
Q2 2020 | $2,750,000 | -22.1% | 57,393 | +2.4% | 0.00% | -25.0% |
Q1 2020 | $3,528,000 | -66.1% | 56,029 | -33.3% | 0.00% | -55.6% |
Q4 2019 | $10,405,000 | +240.7% | 83,965 | +82.4% | 0.01% | +200.0% |
Q3 2019 | $3,054,000 | +19.6% | 46,029 | +43.4% | 0.00% | 0.0% |
Q2 2019 | $2,554,000 | -26.6% | 32,094 | +3.2% | 0.00% | -25.0% |
Q1 2019 | $3,478,000 | +15.5% | 31,088 | +4.1% | 0.00% | 0.0% |
Q4 2018 | $3,010,000 | -5.1% | 29,865 | +19.0% | 0.00% | 0.0% |
Q3 2018 | $3,172,000 | +40.0% | 25,100 | -7.0% | 0.00% | +33.3% |
Q2 2018 | $2,266,000 | +14.0% | 27,000 | -16.4% | 0.00% | 0.0% |
Q1 2018 | $1,987,000 | +5.3% | 32,300 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $1,887,000 | +3.2% | 32,300 | +2.5% | 0.00% | 0.0% |
Q3 2017 | $1,828,000 | -51.3% | 31,500 | +1.6% | 0.00% | -50.0% |
Q2 2017 | $3,753,000 | +9.5% | 31,000 | +2.3% | 0.01% | 0.0% |
Q1 2017 | $3,427,000 | -0.5% | 30,300 | -4.4% | 0.01% | 0.0% |
Q4 2016 | $3,444,000 | -37.2% | 31,700 | -4.8% | 0.01% | -33.3% |
Q3 2016 | $5,481,000 | +7.6% | 33,300 | -6.7% | 0.01% | +12.5% |
Q2 2016 | $5,094,000 | +7.4% | 35,700 | -3.3% | 0.01% | 0.0% |
Q1 2016 | $4,741,000 | +76.4% | 36,900 | +105.0% | 0.01% | +100.0% |
Q4 2015 | $2,688,000 | -9.9% | 18,000 | 0.0% | 0.00% | -20.0% |
Q3 2015 | $2,985,000 | -31.3% | 18,000 | 0.0% | 0.01% | -28.6% |
Q2 2015 | $4,345,000 | +31.2% | 18,000 | 0.0% | 0.01% | +40.0% |
Q1 2015 | $3,313,000 | 0.0% | 18,000 | 0.0% | 0.01% | 0.0% |
Q4 2014 | $3,313,000 | -22.2% | 18,000 | 0.0% | 0.01% | -16.7% |
Q3 2014 | $4,260,000 | -16.7% | 18,000 | -16.7% | 0.01% | -14.3% |
Q2 2014 | $5,111,000 | -14.4% | 21,601 | +5.4% | 0.01% | -22.2% |
Q1 2014 | $5,970,000 | +42542.9% | 20,500 | +10150.0% | 0.01% | – |
Q3 2013 | $14,000 | +55.6% | 200 | 0.0% | 0.00% | – |
Q2 2013 | $9,000 | – | 200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |